期刊
ANNALES D ENDOCRINOLOGIE
卷 80, 期 2, 页码 128-133出版社
MASSON EDITEUR
DOI: 10.1016/j.ando.2018.11.002
关键词
Extrinsic factors; Insulin-producing cells; Pluripotent stem cells; Reprogramming; Stem cells
资金
- National Natural Science Foundation of China [81760150]
- Science and Technology Program of Jiangxi Province [20151BAB205019, 20144BAB2050007]
In the modern world, type-2 diabetes mellitus has become a leading public healthcare problem, due to major risks of morbidity and mortality. Prevalence has increased significantly in recent decades. Treatment involves oral hypoglycemic agents or insulin replacement therapy. Development is ongoing for cell-based diabetes therapies using stem cells with the potential to differentiate into insulin-producing cells (IPCs): embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and stem cells from adult pancreas, liver, central nervous system, bone marrow and adipose tissue. Successful induction of iPSCs, however, depends on the quantity and quality of available stem cells and the development of adapted protocols determining the environment of extrinsic factors and involvement of small molecules. Validating such new cell therapies must be founded on this experimental rationale. (C) 2019 L'Auteur(s). Publie par Elsevier Masson SAS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据